apceth Names Ulrike Verzetnitsch as Chief Technical Officer
News Apr 30, 2015
apceth GmbH & Co. KG is continuing to expand its senior management team and has announced the appointment of Ulrike Verzetnitsch as Chief Technical Officer with immediate effect.
In this newly created role, Ulrike Verzetnitsch will add considerable value to the company by leading apceth’s production facilities and operations and continuing the expansion of its fee-for-service GMP manufacturing business.
Ulrike Verzetnitsch will bring along the broad experience she has gathered in the pharmaceutical sector from her roles in leading pharma and biotech companies. She is joining apceth from her role at Takeda, where she was Head of the Production Unit in Singen, Germany. Before that she held the position of Director of Production with Baxter.
There, she focused on strategic tasks in the final container operation of vaccines and plasma-based and recombinant products. As part of her role, she gained professional experience in the manufacturing of products for worldwide distribution in compliance with the US FDA, EMEA, Japanese and other guidelines. She led the development of new production areas for commercial as well as clinical (phase 1 to 3) production, increased output and developed her organization unit.
Ulrike Verzetnitsch has an education in Biochemistry and holds a Master’s Degree in Chemical Engineering from the Technical University in Vienna, Austria. She started her career in the pharmaceutical industry in the year 2000.
“apceth has recently started phase II of the world’s first clinical trial with genetically modified mesenchymal stem cells in cancer indications and is simultaneously increasing its manufacturing capacity and capabilities as a CMO. It is therefore a very exciting time for us to welcome Ulrike to the team”, said Christine Guenther, CEO of apceth. “Her experience will complement our management team and help drive apceth forward.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE